Simply Oncology

Send us Fan Mail
Join us as we return with the wonderful Professor Mark Beresford from United Hospitals in Bath.
We discuss how we as clinicians describe risk to our patients ans we look at some of the pitfalls of using relative risk, overcomplicated statistics with our patients.
If we cannot explain risk to patients how can they ,make informed decisions.
Mark moves into 'T-shirt Territory' by being our most frequent flyer on the podcast which earns him a coveted Simply Oncology Podcast T-Shirt.

Send us Fan Mail
Join us as we return to our discussion on the fascinating ADePT trial in Glioblastoma brain tumours with the wonderful Dr Faye Robertson from the Western General Hospital, Edinburgh.
We discuss how TGX-007 developed with TROGENIX with its super enhancers, dual payload and delivery system hopes to bring a break through in High grade Gliomas.
We talk about how could this technology be 'rolled out' if successful. What level of success would be needed to develop the specialism for this kind of treatment.
Could this therapy be adapted to be used in other cancer types such as pancreatic cancer etc ?
With only 1 human trial patient clearly this is early days but we hope to follow this trial's progress on The Simply Oncology Podcast.
Even if the survival outcomes of the trial were negative this trials move the dial in terms of what is possible from drug development and delivery.

Send us Fan Mail
Sometimes we hear about a vision for a trial that is so novel and exciting that it takes you back a bit.
This is one such moment.
Join us as we talk to the amazing Dr Faye Robertson from the Edinburgh cancer Centre about the ingenious ADePT trial.

DUAL PAYLOAD GENE THERAPY.
Led by Trogenix and the University of Edinburgh, it tests a breakthrough "Trojan horse" gene therapy designed to destroy cancer cells and stimulate the immune system.
TGX-007 is a drug developed with Tregonix that:
How it Works: It uses dual-payload technology to deliver two distinct therapeutic agents:
HSV-tk: Converts an orally administered antiviral drug (valaciclovir) into a toxic agent that directly kills proliferating tumour cells.
IL-12: Acts as an immune-stimulating cytokine that turns the tumour into an in-situ vaccine, training the body's immune system to attack the cancer and prevent recurrence.
We have had many false dawns in GBM trials but we are very excited by the results so far with TGX-007.

Part 1 of 2 and this is a trial story we want to follow through.

Enjoy!!!

Send us Fan Mail
We return to discuss the role of radiotherapy in the management of Pancreatic Cancer.
What are the side effects of pancreatic radiotherapy and SABR?
Do we need an MR Linac to deliver pancreatic SABR
Where might pancreatic RT sit alongside new RAS inhibitor therapies?
Enjoy

Send us Fan Mail
Today we are talking about the role of radiotherapy in Pancreatic Cancer with the superb Dr Ganesh Radhakrishna from the Christie Hospital in Manchester.
Radiotherapy may play an increasing role in pancreatic cancer. Stereotactic ablative body radiotherapy (SABR) is helping to get excellent control rates in localised pancreatic cancer and may play a role alongside surgery in pancreatic cancer.
Will radiotherapy ever replace surgery in select cases?